- Release Date: 15/05/13 16:31
- Summary: WAV/RULE: TWR: TWR - application for ruling from NZSX Rule 9.1.1
- Price Sensitive: No
- Download Document 10.93KB
TWR 15/05/2013 14:31 WAV/RULE REL: 1431 HRS Tower Limited WAV/RULE: TWR: TWR - application for ruling from NZSX Rule 9.1.1 10 May 2013 NZX Regulation Decision Tower Limited Application for Ruling under NZSX Listing Rule 9.1.1 Background 1. Tower Limited ("TWR") is a Listed Issuer with ordinary shares quoted on the NZX Main Board. 2. TWR's business activities comprise the provision of insurance products and, until April 2013, certain investment products. 3. On 2 November 2012 TWR announced that it had sold its Health insurance business unit to nib Holdings Limited for $102 million (the "Health Transaction"). On 26 February 21012 TWR announced that it had sold its Investment business unit to Fisher Funds Limited for $79 million (the "Investment Transaction"). 4. At its annual meeting of 21 March 2013 TWR announced that it had sold the Health and Investment business units following a comprehensive strategic review conducted by the senior executive team. 5. On 10 May 2013 TWR announced that it had sold most of its Life insurance business unit to Fidelity Life Assurance Company Limited (the "Life Transaction"). TWR will sell most of its non-participating life insurance policies and retain the capital currently held against those policies, releasing an aggregate value of $189 million. 6. Following the Life Transaction, TWR will retain its 'participating book' and other run-off life insurance assets, which have an embedded value of $23 million. 7. TWR's Average Market Capitalisation ("AMC") over the 20 Business Days preceding 10 May 2013 was approximately $365.8 million. 8. The gross value of assets divested under the Health Transaction and Investment Transaction were in both cases below 50% of TWR's AMC at the time those transactions were announced. 9. NZSX Listing Rule ("Rule") 9.1.1 prohibits an Issuer, except with the prior approval of an ordinary resolution of shareholders, from entering a transaction or series of linked or related transactions to dispose of assets which would change the essential nature of the business of the Issuer, or in respect of which the gross value is in excess of 50% of the Issuer's AMC. Application 10. TWR has applied to NZX Regulation ("NZXR") for a Ruling that Rule 9.1.1 does not apply in respect of the Life Transaction, and that TWR will not be required to seek shareholder approval for the divestment of part of the Life Business. 11. In support of its application for a Ruling, TWR makes the following submissions: (a) The Life Transaction will not change the essential nature of TWR's insurance business because: (i) TWR considers itself an insurer and has operated and continues to operate within the insurance industry. It is in the business of providing insurance. It is not seeking to go in a new business direction. TWR considers that its shareholders view it as an insurance company, rather than a life insurer. (ii) TWR is not disposing of all of its Life insurance business. TWR is retaining the closed books of business, including the Whole of Life and Endowment Policies, annuities and life bonds issued by Tower Life (N.Z.) Limited which currently have annual premium revenue of more than $10 million and assets backing the policies of more than $700 million. This retained business is expected to continue to operate for at least 70 years. (iii) NZXR's 2005 Kiwi Income Property Trust decision in respect of Capital Properties New Zealand Limited stated that the 'essential nature' of a business depends upon the business sector in which an issuer carries on its business. TWR does not consider that a divestment of part of the Life Business (as described above), which would leave TWR predominantly as a general insurer, would amount to a change in the essential nature of TWR's insurance business. TWR would be retaining its largest business unit (by revenue) as well as residual life business. TWR's main undertaking will remain the same following the proposed sale of the Life Business as TWR will still carry on the business of an insurer. (iv) Examples of where shareholder approval has been required for a change in the essential nature of a business include, Max Industries Limited which changed from being a gold mining investment company to an organic fertiliser manufacturer (1997). Similarly, TRS Investments Limited changed its business from corporate training to investment (2007). These represent clear changes in the essential nature or business direction of the business for those companies across different industries. TWR does not consider that it will change the essential nature of its business by selling down parts of its life insurance business. TWR will remain a general insurer with a smaller life insurance presence. (v) TWR has received in-principle advice from ASX that it does not consider shareholder approval is required under the ASX Listing Rules for the sale of the Life Business. In coming to its conclusion that shareholder approval is not required, ASX considered (under the ASX Listing Rules) whether the sale of the Life Business would result in a 'significant change to the nature or scale' of TWR's business activities, similar to the wording in Listing Rule 9.1.1(a). While the in-principle decision is not technically binding, ASX notes that it provides a high degree of certainty as to ASX's approach when formal notification occurs upon signing of the transaction. (b) TWR has illustrated to NZXR that the gross value of the assets sold under the Life Transaction are below 50% of TWR's AMC as at 10 May 2013. On completion of the Life Transaction, given the nature of the business, there will be a purchase price adjustment to reconcile the 30 September 2012 'value of policies in force' figures to actual figures. TWR will then release final transaction information to the market. (c) The Health Transaction, Investment Transaction and Life Transaction are not a linked or related series of transactions for the purposes of Rule 9.1.1 because: (i) An outcome of the strategic review described at the 2013 annual meeting was that the full value of TWR's operations across four business units was not reflected in TWR's share price. TWR considered proposals including acquisitions, operational alliances and divestment of assets with a view to maximise shareholder value. There was no expected outcome from the exercise, and any transactions had to make sound business sense before being progressed. The strategic review did not determine that TWR should undertake the Health Transaction, Investment Transaction and Life Transaction and all proposals were to be considered on their merits. (ii) The inclusion of the wording 'series of linked or related transactions' in Rule 9.1.1 is intended to be an anti-avoidance mechanism, and not intended to link genuinely separate transactions. The provision is intended to prevent an issuer from selling off certain assets in smaller transactions to the same or related parties (for example, selling a key part of the business incrementally) to avoid triggering Rule 9.1.1 or the major transaction test under the Companies Act. (iii) Each of the Health Transaction, Investment Transaction and Life Transactions have been independently negotiated with no guarantee one or more would proceed. (iv) Other transactions relating to the divested assets had been considered prior to the 2012 strategic review. The Health Transaction, Investment Transaction and Life Transactions were therefore not derived from the outcomes of the strategic review. (v) None of the Transactions were conditional on one or more of the others proceeding, that is entry into one transaction did not promote entry into any other transaction or influence their terms and conditions. Rule 9.1.1 12. Rule 9.1.1 provides that: An Issuer shall not (subject to Rule 9.1.3) enter into any transaction or series of linked or related transactions to acquire, sell, lease, exchange, or otherwise dispose of (otherwise than by way of charge) assets of the Issuer or assets to be held by the Issuer: (a) which would change the essential nature of the business of the Issuer: or (b) in respect of which the gross value is in excess of 50% of the Average Market Capitalisation of the Issuer; except with the prior approval of an Ordinary Resolution of the Issuer or special resolution if that Issuer must obtain approval of the transaction or transactions by a special resolution under section 129 of the Companies Act 1993. Decision 13. On the basis that the information provided to NZXR is full and accurate in all material respects, NZXR Rules that Rule 9.1.1 does not apply to the Life Transaction. Reasons 14. In coming to this decision, NZXR has considered the following matters: ? (a) The Life Transaction, in and of itself, does not require shareholder approval because it does not trigger Rule 9.1.1(a). The divestment will not result in a change to the essential nature of TWR's business as a general and life insurer. NZXR considered that TWR's core business is that of a general and life insurer, and after completing the Life Transaction will continue to be a general and life insurer. (b) The Life Transaction, in and of itself, does not require shareholder approval because it does not trigger Rule 9.1.1(b). TWR has submitted and NZXR accepts that the value of assets divested under the Life Transaction is below 50% of TWR's AMC as at 10 May 2013. Rule 9.1.1(b) applies only where the gross value of the assets divested are more than or equal to 50% of an issuers AMC. NZXR understands that on completion of the Life Transaction there will be a purchase price adjustment in order to reconcile the 30 September 2012 'value of policies in force' figures to actual figures at which time TWR will release final transaction information to the market. (c) NZXR is satisfied that there is insufficient nexus between the Health Transaction, the Investment Transaction and the Life Transaction (the "Tower Transactions") that would result in the Tower Transactions being considered a 'series of linked or related transactions' for the purposes of the Rule. (i) NZXR agrees the words 'series of linked or related transactions' can operate as an anti-avoidance mechanism but notes that the Rule goes further and may capture transactions that come out of a concerted plan or that form part of a scheme and that are proximate in time. Transactions with different parties may be a series of linked or related transactions if they are part of a concerted plan or form part of a scheme. (ii) The so-called strategic review was not a plan or strategy in itself, but a process by which a number of possible options for maximising shareholder value could be considered and executed. Each of the Tower Transactions was conceived and executed independently of each other and were not part of a concerted plan towards achieving a single strategic objective. Therefore, the only 'link' between the Tower Transactions is their proximity in time which is not in itself a sufficient nexus for them to be a series of linked or related transactions. ENDS. End CA:00236261 For:TWR Type:WAV/RULE Time:2013-05-15 14:31:18
- Forums
- NZX - By Stock
- TWR
- Ann: WAV/RULE: TWR: TWR - application for ruling
Ann: WAV/RULE: TWR: TWR - application for ruling
Featured News
Add TWR (NZSX) to my watchlist
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online